Compare PKOH & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | ABEO |
|---|---|---|
| Founded | 1907 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.5M | 280.2M |
| IPO Year | N/A | 1980 |
| Metric | PKOH | ABEO |
|---|---|---|
| Price | $24.28 | $5.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 20.8K | ★ 1.3M |
| Earning Date | 03-04-2026 | 03-19-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 30.26 | N/A |
| EPS | ★ 1.68 | 1.29 |
| Revenue | ★ $1,592,500,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | $1,589.77 |
| P/E Ratio | $14.43 | ★ $4.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.52 | $3.93 |
| 52 Week High | $26.31 | $7.54 |
| Indicator | PKOH | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 65.99 | 47.26 |
| Support Level | $21.17 | $4.79 |
| Resistance Level | $24.00 | $5.42 |
| Average True Range (ATR) | 0.90 | 0.28 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 88.27 | 31.26 |
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.